Efficacy of vaccine responses against SARS-Cov-2 in patients with giant cell arteritis and polymyalgia rheumatica (GPSVAC)

Efficacy of vaccine responses against SARS-Cov-2 in patients with giant cell arteritis and polymyalgia rheumatica (GPSVAC) - GPSVAC

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON51139

Enrollment

Registered

2021-05-17

Start date

2021-05-20

Completion date

Unknown

Last updated

2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Giant cell arteritis / Temporal arteritis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: In order to be eligible to participate in this study, a subject must meet all of the following criteria: Give written informed consent Diagnosed with GCA or PMR

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: Concomitant chronic diseases that may affect the immune system (such as prior or current malignant disease, active infectious disease, other rheumatic disease, kidney disease, active allergy etc.) Severe anaemia defined as a hemoglobin of less than 6,0 g/dL Confirmed SARS-CoV-2 infection (current or previous)

Design outcomes

Primary

Measure	Time frame
Assessment of humoral (antibody) immune responses to the coronavirus vaccine in GCA/PMR patients compared to the reference values and to matched healthy controls.	—

Secondary

Measure	Time frame
Assessment of cellular (T-cell) immune responses to the coronavirus vaccine in GCA/PMR patients Documentation of vaccination side-effects	—

Countries

Netherlands

Outcome results